Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized controlled trial of rituximab for psychotic disorder in adults
2024-512408-20-00Phase 2Completed
- Sponsor
- Region Örebro län
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of rituximab in Schizophrenia Spectrum and Other Psychotic Disorders (SZ) (2 arms), sponsored by Region Örebro län. Primary endpoints: Positive and Negative Syndrome Scale total score and PANSS depression item A6. Started Aug 2024; status: completed.
02
Drugs
rituximab
03
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders (SZ)
Beyond the preview
Go deeper on 2024-512408-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512408-20-00.